DocuSign Envelope ID: 19F79C22-5AF2-4E36-871D-8EA303499FCD

FORM 11

NOTICE OF PROPOSED STOCK OPTION GRANT OR AMENDMENT

Name of Listed Issuer: Beyond Medical Technologies Inc. (the "**Issuer**").

Trading Symbol: DOCT

Date: January 12, 2022

1. New Options Granted:

Date of Grant: January 10, 2022

Name of Optionee	Position (Director/ Officer/ Employee/ Consultant/ Management Company	Insider Yes or No?	No. of Optioned Shares	Exercise Price	Expiry Date	No. of Options Granted in Past 12 Months
Milan Malhi	Corporate Development Officer	No	250,000	$0.075	January 10, 2027	250,000
Michael Kelly	Director	Yes	100,000	$0.075	January 10, 2027	Nil
Hyder Khoja	Director	Yes	100,000	$0.075	January 10, 2027	100,000
Harvey Sidhu	Director	Yes	200,000	$0.075	January 10, 2027	250,000
Alfred Wong	Corporate Development Officer	No	150,000	$0.075	January 10, 2027	Nil
Zara Kanji	Officer	Yes	150,000	$0.075	January 10, 2027	Nil
Sheona Docksteader	Officer	Yes	150,000	$0.075	January 10, 2027	Nil
Kal Malhi	Director	Yes	1,000,000	$0.075	January 10, 2027	Nil

Total Number of optioned shares proposed for acceptance: 2,100,000

2. Other Presently Outstanding Options:

DocuSign Envelope ID: 19F79C22-5AF2-4E36-871D-8EA303499FCD

Name of Optionee	No. of Optioned Shares	Exercise Price	Original Date of Grant	Expiry Date
Hyder Ali Khoja	100,000	$0.60	October 25, 2017	October 25, 2022
Kal Malhi	150,000	$0.60	October 25, 2017	October 25, 2022
Alfred Wong	125,000	$0.60	October 25, 2017	October 25, 2022
Alfred Wong	150,000	$0.72	April 8, 2019	April 8, 2024
Hyder Ali Khoja	100,000	$0.125	January 12, 2021	January 12, 2023
Milan Malhi	250,000	$0.125	January 12, 2021	January 12, 2023
Cairo Malhi	250,000	$0.125	January 12, 2021	January 12, 2023
Harveer Sidhu	250,000	$0.125	January 12, 2021	January 12, 2023
Total	**1,375,000**			

3. Additional Information

(a) If shareholder approval was required for the grant of options (including prior approval of a stock option plan), state the date that the shareholder meeting approving the grant was or will be held.

Not applicable.

(b) State the date of the news release announcing the grant of options.

January 11, 2022

(c) State the total issued and outstanding share capital at the date of grant or amendment.

79,139,750

(d) State, as a percentage of the issued and outstanding shares of the Issuer indicated in (c) above, the aggregate number of shares that are subject to incentive stock options, including new options, amended options and other presently outstanding options.

DocuSign Envelope ID: 19F79C22-5AF2-4E36-871D-8EA303499FCD

4.39%

(e) If the new options are being granted pursuant to a stock option plan, state the number of remaining shares reserved for issuance under the plan.

4,438,975

(f) If the Issuer has completed a public distribution of its securities within 90 days of the date of grant, state the per share price paid by the public investors.

Not applicable.

(g) Describe the particulars of any proposed material changes in the affairs of the Issuer.

Not applicable

DocuSign Envelope ID: 19F79C22-5AF2-4E36-871D-8EA303499FCD

4 Certificate of Compliance

The undersigned hereby certifies that:

1. The undersigned is a director and/or senior officer of the Issuer and has been duly authorized by a resolution of the board of directors of the Issuer to sign this Certificate of Compliance.

2. As of the date hereof there is no material information concerning the Issuer which has not been publicly disclosed.

3. The undersigned hereby certifies to the Exchange that the Issuer is in compliance with the requirements of applicable securities legislation (as such term is defined in National Instrument 14-101) and all Exchange Requirements (as defined in CNSX Policy 1).

4. All of the information in this Form 11 Notice of Proposed Stock Option Grant or Amendment is true.

Dated January 12, 2022.

Kulwant Malhi
Name

DocuSigned by:
Kal Malhi
3E7089E93F24489...
Signature

CEO
Official Capacity